COLL Q3 2022 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$127M+61.1% YoY

Gross Profit

$59M46.3% margin

Operating Income

$20M16.1% margin

Net Income

$457,0000.4% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+2.8%

Cash Flow

Operating Cash Flow

$43M

Free Cash Flow

$43M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$1.0B

Stockholders' Equity

$197M

Cash & Equivalents

$134M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$127M	$79M	+61.1%
Gross Profit	$59M	$46M	+27.6%
Operating Income	$20M	$14M	+44.7%
Net Income	$457,000	$8M	-94.3%

Revenue Segments

Xtampza ER

$39M31%

Belbuca

$39M31%

Nucynta IR

$27M21%

Nucynta ER

$17M13%

Symproic

$4M3%

Other

$1M1%

Elyxyb

$218,0000%